A Phase 3 interventional study of Ferric derisomaltose and Ferrous sulfate in Iron Deficiency Anemia and Pregnancy, sponsored by Women and Infants Hospital of Rhode Island. Recruiting at 8 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Women and Infants Hospital of Rhode Island · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 8 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 8th largest by planned enrollment, is one of 3 that started in 2023, is one of 18 in phase 3, and was the 25th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →8 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Women only
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
Sun Yat-sen University · Sites in China
Ages 18–65
Baylor College of Medicine · Sites in United States
Ages 18–65 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2007; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 300 is above the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 121 across the 32 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
Women and Infants Hospital of Rhode Island is the lead sponsor of 93 studies on the registry; 25 are open to participants now.
Women and Infants Hospital of Rhode Island has 1 study filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
3 of the studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462704Phase 3Women and Infants Hospital of Rhode IslandIntravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy | 2027-03-30 |
| NCT06884280Phase 3Hull University Teaching Hospitals NHS TrustComparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study | 2027-10 |
| NCT04913649dr. P. NoordzijIntravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<30 ng/mL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment.
Iron-deficiency anemia (IDA) is a common, undertreated problem in pregnancy. According to data from the U.S. National Health and Nutrition Examination Survey (NHANES), 25% of pregnant women in the U.S. have iron deficiency, with rates of 7%, 24%, and 39% in the first, second, and third trimesters, respectively. The prevalence of IDA is estimated at 16.2% overall and up to 30% at delivery. Iron deficiency is associated with significant adverse maternal and fetal outcomes including blood transfusion, cesarean delivery, depression, preterm birth, and low birth weight. Moreover, iron-deficient mothers are at risk of delivering iron-deficient neonates who, despite iron repletion, remain at risk for delayed growth and development. While treatment with iron supplementation is recommended during pregnancy, questions remain about the optimal route of delivery. Oral iron therapy, the current standard, is often suboptimal: up to 70% of patients experience significant gastrointestinal side effects (nausea, constipation, diarrhea, indigestion, and metallic taste) that prevent adherence to treatment, resulting in persistent anemia. Intravenous (IV) iron is an attractive alternative because it mitigates the adherence and absorption challenges of oral iron. However, IV iron costs more, and there are historical concerns about adverse reactions.
The American College of Obstetricians and Gynecologists (ACOG) recommends oral iron for the treatment of IDA in pregnancy, with IV iron reserved for the restricted group of patients. Our preliminary data show that this approach leads to 30% of patients with persistent IDA at delivery and an associated 3 to 6-fold increased risk of peripartum blood transfusion. ACOG's preferential recommendation of oral iron is based on paucity of data on the benefits and safety of IV iron, compared with oral iron, in pregnancy. Our published systematic review and meta-analysis showed that IV iron is associated with greater increase in maternal hemoglobin (Hb), but most of the primary trials were conducted in developing countries, included small sample sizes (50 - 252), and did not assess meaningful maternal and neonatal outcomes. The current Cochrane review noted that despite the high incidence and disease burden associated with IDA in pregnancy, there is paucity of quality trials assessing clinical maternal and neonatal effects of iron administration in women with anemia. The authors called for "large, good quality trials assessing clinical outcomes." The only large randomized trial of IV versus oral iron, conducted in India, showed no difference in a maternal composite outcome, but it is limited by use of iron sucrose which required five infusions, resulting in a wide range of iron doses (200 - 1600 mg). In addition, the primary composite outcome included some components not directly related to anemia. In contrast, our pilot trial of a single infusion of 1000 mg of IV low molecular weight iron dextran in pregnant women in the U.S. with moderate-to-severe IDA significantly reduced the rate of maternal anemia at delivery and showed promise for improving maternal morbidity by reducing rates of blood transfusion.
This is the first definitive double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<30 ng/mL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment. A multidisciplinary team of investigators in the U.S., will pursue the following specific aims:
Primary Aim: Evaluate the effectiveness and safety of IV iron, compared with oral iron, in reducing the rate of anemia at delivery in pregnant women with IDA.
Secondary Aim 1: Estimate the cost-effectiveness of IV iron , compared with oral iron, in pregnant women with IDA as measured by incremental cost per Quality Adjusted Life-year (QALY).
Secondary Aim 2: Assess the effect of IV iron, compared with oral iron, on offspring brain myelin content and neurodevelopment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes and daily placebo tablets until delivery.
Drug: Ferric derisomaltose
Participants assigned to the oral iron group will receive a single 250 mL IV normal saline infusion given over 20 minutes and 325mg tablets of ferrous sulfate (65 mg of elemental iron) to be taken until delivery.
Drug: Ferrous sulfate
Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
Also known as: Monoferric
325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
Also known as: Ferosul
Rate of maternal anemia (hgb<11mg/dL) at delivery
Hemoglobin \<11mg/dL on admission to inpatient obstetrics unit for labor and delivery
Time frame: Within 24 hours of admission to inpatient obstetrics unit for delivery of infant
Concentration of maternal hemoglobin at delivery
Hemoglobin on admission to inpatient obstetrics unit for labor and delivery
Time frame: Within 24 hours of admission to inpatient obstetrics unit for delivery of infant
Rate of maternal blood transfusion at delivery
Maternal blood transfusion from delivery to 7 days postpartum
Time frame: Delivery to 7 days postpartum
Concentration of maternal ferritin at delivery
Maternal ferritin on admission to inpatient obstetrics unit for labor and delivery
Time frame: Within 24 hours of admission to inpatient obstetrics unit for delivery of infant
Concentration of maternal hemoglobin postpartum day 1
Maternal hemoglobin on postpartum day 1
Time frame: On day after participant delivered her infant; postpartum day 1
Rate of cesarean delivery
Cesarean delivery for any indication in patients without prior cesarean deliveries
Time frame: Once at infant delivery
Rate of severe infusion adverse events
Safety and tolerability
Time frame: 2 days after intravenous iron or placebo infusion
Rate of mild medication adverse events
Safety and tolerability
Time frame: 4 weeks after initiation of oral iron or placebo
Edinburgh Perinatal Depression Scale score
Edinburgh Perinatal Depression Scale score. Minimum score 0, maximum score 30, higher scores indicate worse depressive symptoms.
Time frame: At randomization (baseline) and at 4-6 weeks postpartum
Maternal EuroQol Group Quality-of-Life Questionnaire score
Maternal EuroQol Group Quality-of-Life Questionnaire (EQ-5D-5L). Minimum score 11111 (full health), maximum score 55555 (worst health), higher scores indicate worse quality of life.
Time frame: At 6 weeks postpartum by phone or in person
Rate of Maternal infection
Any infection diagnosed from initiation of treatment until 6 weeks postpartum
Time frame: From initiation of treatment until 6 weeks postpartum
Rate of Composite Maternal Complications
Maternal mortality or any one of several maternal morbidities
Time frame: At 6 weeks postpartum
Gestational age at delivery
Gestational age at delivery
Time frame: At delivery
Rate of preterm birth at less then 37 weeks
Preterm birth; gestational age at delivery at less than 37 weeks (spontaneous or indicated)
Time frame: At delivery
Rate of Neonatal Intensive Care Unit Admission
Admission to the neonatal intensive care unit for any indication
Time frame: At birth through through 30 days from birth
Neonatal birth weight
Infant birth weight
Time frame: At birth
Concentration of umbilical artery pH
Concentration of umbilical artery pH from umbilical cord gases from infant umbilical cord segment at birth
Time frame: At birth
Concentration of umbilical artery bicarbonate
Concentration of umbilical artery bicarbonate from umbilical cord gases from infant umbilical cord segment at birth
Time frame: At birth
Concentration of umbilical artery base excess
Concentration of base excess from umbilical cord gases from infant umbilical cord segment at birth
Time frame: At birth
Concentration of umbilical artery lactate
Concentration of umbilical artery lactate from umbilical cord gases from infant umbilical cord segment at birth
Time frame: At birth
Concentration of neonatal hemoglobin
Concentration of neonatal hemoglobin from umbilical cord blood at birth or first neonatal complete blood count
Time frame: At birth
Concentration of neonatal ferritin
Concentration of neonatal ferritin from umbilical cord blood at birth or first neonatal blood draw
Time frame: At birth
Neonatal Apgar scores
Apgar scores at 1 and 5 minutes of life. Minimum score 0, maximum score 10, higher scores indicate better well being.
Time frame: At 1 minute and 5 minutes of life
Rate of composite neonatal complication
Neonatal mortality or any one of several neonatal morbidities
Time frame: Through 30 days from birth
Concentration of child brain myelin
Concentration of infant brain myelin from magnetic resonance imaging
Time frame: At an average of 6 months and 36 months
Child Mullen Scale of Early Learning Score
Mullen Scale of Early Learning Score as percentile. Minimum score 1, maximum score 99, higher scores indicate better neurodevelopment.
Time frame: At an average of 6 months and 36 months
Plan to share: Yes — Data will be collected from human subjects and will be shared according to NIH guidelines. The investigators are committed to the sharing of final data, being mindful that the rights and privacy of people who participate in research must be protected at all times. The investigators will make a complete study dataset available for sharing. The investigators will have a description of study dataset, including code books, meta-data related to the dataset, and documented programming code used for creating the final study population, for creating variables, and for conducting all outcomes analyses. The investigators will remain HIPAA compliant, and therefore any datasets resulting from participants will be free of any identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of individual subjects.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: 5 years after completion of study
Access criteria: The investigators will make the data and associated documentation available to users under a data-sharing agreement that provides for commitment to: a) using the data only for research purposes and not to identify any individual participant; b) securing the data using appropriate computer technology; and c) destroying or returning the data after analyses are completed. Timelines for distribution of data will vary depending on any required restrictions as mentioned above. Data may be distributed by a number of electronic methods, including web-based databases, datasets, and spreadsheets, or via electronic media such as compact discs.
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Mar 2027, 50 months after the start.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000
Women and Infants Hospital of Rhode Island